Bellicum Pharmaceuticals, Inc.(Nasdaq: BLCM) announced results from the BP-004 multicenter clinical trial which includes children with Primary Immune Deficiencies (PIDs) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE